John M. McCall
16 Papers
34 Citations
John M. McCall is an academic researcher. The author has contributed to research in topics: Duchenne muscular dystrophy & Muscular dystrophy. The author has an hindex of 11, co-authored 16 publications.
Chat about Author
Papers
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects
Christopher R. Heier,Jesse M. Damsker,Qing Yu,Blythe C. Dillingham,Tony Huynh,Jack H. Van der Meulen,Arpana Sali,Brittany K. Miller,Aditi Phadke,Luana Scheffer,James L Quinn,Kathleen Tatem,Sarah Jordan,Sherry Dadgar,Olga Rodriguez,Chris Albanese,Michael E. Calhoun,Heather Gordish-Dressman,Jyoti K. Jaiswal,Edward M. Connor,John M. McCall,Eric P. Hoffman,Erica K.M. Reeves,Kanneboyina Nagaraju +23 more
TL;DR: Successful improvement of dystrophy independent of hormonal, growth, or immunosuppressive effects is demonstrated, indicating VBP15 merits clinical investigation for DMD and would benefit other chronic inflammatory diseases.
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.
Laurie S. Conklin,Jesse M. Damsker,Eric P. Hoffman,William J. Jusko,Panteleimon D. Mavroudis,Benjamin D Schwartz,Laurel J Mengle-Gaw,Edward C. Smith,Jean K. Mah,Michela Guglieri,Yoram Nevo,Nancy L. Kuntz,Craig M. McDonald,Mar Tulinius,Monique M. Ryan,Richard Webster,Diana Castro,Richard S. Finkel,Andrea L. Smith,Lauren P. Morgenroth,Antonio Arrieta,Maya Shimony,Mark Jaros,Phil Shale,John M. McCall,Yetrib Hathout,Kanneboyina Nagaraju,John N. van den Anker,Leanne M Ward,Alexandra Ahmet,Michaelyn R. Cornish,Paula R. Clemens +31 more
TL;DR: The development of the first dissociative steroid that preserves anti‐inflammatory efficacy and decreases steroid‐associated safety concerns is demonstrated, with an array of pre‐selected biomarkers in multiple contexts of use.
89
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
Eric P. Hoffman,Benjamin D Schwartz,Laurel J Mengle-Gaw,Edward C. Smith,Diana Castro,Jean K. Mah,Craig M. McDonald,Nancy L. Kuntz,Richard S. Finkel,Michela Guglieri,Katharine Bushby,Mar Tulinius,Yoram Nevo,Monique M. Ryan,Richard D. Webster,Andrea L. Smith,Lauren P. Morgenroth,Antonio Arrieta,Maya Shimony,Catherine Siener,Mark Jaros,Phil Shale,John M. McCall,Kanneboyina Nagaraju,John N. van den Anker,Laurie S. Conklin,Avital Cnaan,Heather Gordish-Dressman,Jesse M. Damsker,Paula R. Clemens +29 more
TL;DR: This study provides Class IV evidence that for boys with DMD, vamorolone demonstrated possible efficacy compared to a natural history cohort of glucocorticoid-naive patients and appeared to be tolerated.
75
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Eric P. Hoffman,Erica K.M. Reeves,Jesse M. Damsker,Kanneboyina Nagaraju,John M. McCall,Edward M. Connor,Kate Bushby +6 more
TL;DR: A new trial, FOR-DMD, aims to address a gap in knowledge in the area of "dissociative steroids," drugs that are able to better separate efficacy and side effects, providing a broader therapeutic window.
67
Δ-9,11 Modification of Glucocorticoids Dissociates Nuclear Factor-κB Inhibitory Efficacy from Glucocorticoid Response Element-Associated Side Effects
Andreas R. Baudy,Erica K.M. Reeves,Jesse M. Damsker,Christopher R. Heier,Lindsay M. Garvin,Blythe C. Dillingham,John M. McCall,Sree Rayavarapu,Zuyi Wang,Jack Vandermeulen,Arpana Sali,Vanessa E. Jahnke,Stephanie Duguez,Debra C. DuBois,Mary C. Rose,Kanneboyina Nagaraju,Eric P. Hoffman +16 more
TL;DR: The data demonstrate that a Δ-9,11 analog dissociates the GR-mediated transcriptional activities from anti-inflammatory activities, and may hold promise as a source of safer therapeutic agents for chronic inflammatory disorders.
31